Sanai Health Industry Group Company Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022. The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.027 HKD | +8.00% | -10.00% | -57.81% |
1st Jan change | Capi. | |
---|---|---|
-57.81% | 13.2M | |
+34.00% | 704B | |
+26.24% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.04% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- 1889 Stock
- News Sanai Health Industry Group Company Limited
- Sanai Health Industry Group Company Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023